FDA cited Premier Nutra Pharma, a Carlsbad, California contract maker of nasal spray drugs, for CGMP violations after microbial contamination.
What happened
FDA inspected Premier Nutra Pharma's Carlsbad, California facility from July 5 to July 8, 2022 and found the company did not follow CGMP (current good manufacturing practice, the FDA's required quality rules for drug manufacturing). A nasal spray batch was contaminated with yeast and reached the market; the customer recalled it. An ingredient used in several products was visibly contaminated with bees and/or yeast but was still used, and the firm had no cleaning procedures, no environmental monitoring and no batch records.
What FDA found
The firm did not investigate microbial contamination of a nasal spray batch, nor check whether other batches were similarly contaminated, even though an ingredient used in several products was visibly contaminated with bees and/or yeast.
21 CFR 211.192The firm had no written procedures to prevent microbial contamination: no environmental monitoring, no microbiological testing of facilities or equipment, and no cleaning procedures or records.
21 CFR 211.113(a)The firm did not test each batch of drug product to show it was free of objectionable microorganisms.
21 CFR 211.165(b)The firm had no batch production and control records for its formulation, filling and packaging operations, so it could not show its products were the same from batch to batch.
21 CFR 211.188The firm had no quality unit (the independent group that reviews and releases batches) and no written procedures for its duties, such as batch record review, annual product review, deviations, corrective actions, complaints, retain samples and recalls.
21 CFR 211.22(a) and 211.22(d)
What FDA wants
FDA tells the firm to respond in writing within 15 working days with independent assessments of its investigations and manufacturing operations, a microbiological risk assessment, test results for retained batches, and corrective action plans. The firm must also notify FDA before resuming drug manufacturing, since it told FDA it had stopped production.
Who should pay attention
- brands that contract-manufacture OTC nasal sprays or other drugs at this firm
- companies that buy or distribute nasal spray drug products
- quality teams at contract manufacturers handling non-sterile drug production
This is a summary. Read the original letter on fda.gov.